Machine learning algorithm outperforms tests in diagnosing early Alzheimer's

Diagnosing Alzheimer’s in its early stages is key to providing patients with proper delaying or preventive drugs. A new study, published in Scientific Reports, explains how a machine learning algorithm could be used to predict the onset of the disease.

Developed by researchers at Case Western Reserve University, the computer machine learning algorithm takes into account measurements from magnetic resonance imaging (MRI) scans, the state of the hippocampus, the brain's glucose metabolism, proteomics, genomics, mild cognitive impairment and other factors to predict a patient’s risk of developing Alzheimer’s.

"Many papers compare the healthy to those with the disease, but there's a continuum," said Anant Madabhushi, F. Alex Nason professor II of biomedical engineering at Case Western Reserve. "We deliberately included mild cognitive impairment, which can be a precursor to Alzheimers, but not always. The algorithm assumes each parameter provides a different view of the disease, as if each were a different set of colored spectacles.”

The study enrolled 149 patients, taken from the Alzheimer's Disease Neuroimaging Initiative, and analyzed data on two sets. The first set tested the algorithm's ability to differentiate healthy patients from those who were not, while the second set tested its ability to identify which patients had mild cognitive impairment and who had Alzheimer’s. The algorithm was able to outperform other methods of detecting Alzheimer’s diseases before symptoms interfered with patients' daily lives.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.